Auris Medical Holding AG (EARS) Given Daily Media Impact Rating of 0.18

Media stories about Auris Medical Holding AG (NASDAQ:EARS) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Auris Medical Holding AG earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.200586644106 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Receive News & Ratings for Auris Medical Holding AG Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.

These are some of the headlines that may have effected Accern Sentiment’s analysis:

Auris Medical Holding AG (EARS) Drops Lower Over Past 5 Sessions – Evergreen Caller (evergreencaller.com)
Discounted Stock Alert on Auris Medical Holding AG (NASDAQ:EARS) – FLBC News (flbcnews.com)
Delving Into The Numbers For Auris Medical Holding AG (EARS) – FLBC News (flbcnews.com)
Looking for a Catalyst: What Are the Technicals Saying About Auris Medical Holding AG (EARS)? – Bulletin News (orobulletin.com)
Keen Investors Taking a Look at Auris Medical Holding AG … – FLBC News (flbcnews.com)

A number of equities research analysts recently issued reports on EARS shares. Roth Capital reissued a “buy” rating and set a $5.00 price target on shares of Auris Medical Holding AG in a research note on Saturday, July 1st. ValuEngine lowered Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. Auris Medical Holding AG currently has an average rating of “Hold” and an average price target of $3.42.

Shares of Auris Medical Holding AG (NASDAQ EARS) traded down 1.2412% during midday trading on Friday, hitting $0.7161. The company had a trading volume of 47,115 shares. The company’s market capitalization is $31.74 million. Auris Medical Holding AG has a 12 month low of $0.60 and a 12 month high of $2.25. The company has a 50-day moving average of $0.81 and a 200-day moving average of $0.80.

Auris Medical Holding AG (NASDAQ:EARS) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.09. Analysts predict that Auris Medical Holding AG will post ($0.63) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “[[title]]” was first reported by [[site]] and is the property of of [[site]]. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at [[permalink]].

About Auris Medical Holding AG

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.